Mixed options sentiment in ImmunityBio (IBRX), with shares up 29c, or 3.53%, near $8.50. Options volume relatively light with 9513 contracts traded and calls leading puts for a put/call ratio of 0.06, compared to a typical level near 0.28. Implied volatility (IV30) dropped 0.96 near 114.81,and above the 52wk median, suggesting an expected daily move of $0.61. Put-call skew steepened, indicating increased demand for downside protection.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IBRX:
- Buy Rating on ANKTIVA: NCCN Guideline Expansion, Off‑Label Upside, and DCF‑Backed Risk‑Reward in BCG‑Unresponsive NMIBC
- Expanding ANKTIVA’s NMIBC Opportunity: NCCN Endorsement, FDA Flexibility, and Strengthening Long‑Term Prospects for ImmunityBio
- ImmunityBio announces NCCN Guidelines for Bladder Cancer to include Anktiva
- Mixed options sentiment in ImmunityBio with shares down 2.26%
- Morning Movers: Adobe falls with Narayen set to exit as CEO